Johnson AC - Search Results

1

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Franconieri F, Deshayes S, de Boysson H, Trad S, Martin Silva N, Terrier B, Bienvenu B, Galateau-Sallé F, Emile JF, Johnson AC, Aouba A. Franconieri F, et al. Among authors: johnson ac. Oncoimmunology. 2018 Apr 9;7(8):e1450712. doi: 10.1080/2162402X.2018.1450712. eCollection 2018. Oncoimmunology. 2018. PMID: 30221042 Free PMC article.

2

Efficacy and Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone Marrow Infiltration.

DA Silva A, Levy C, Allouache D, Hrab I, Morel A, Faveyrial A, Gunzer K, Johnson A, Segura C, Licaj I, Damaj G, Emile G. DA Silva A, et al. Anticancer Res. 2020 May;40(5):2955-2960. doi: 10.21873/anticanres.14274. Anticancer Res. 2020. PMID: 32366448

3

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.

Johnson AC, Matias M, Boyle H, Escudier B, Molinier A, Laguerre B, Helissey C, Brachet PE, Dugué AE, Mourey L, Coquan E, Joly F. Johnson AC, et al. BMC Cancer. 2017 May 22;17(1):355. doi: 10.1186/s12885-017-3312-7. BMC Cancer. 2017. PMID: 28532444 Free PMC article.

4

Uptake of Radium-223 Dichloride and Early [¹⁸F]NaF PET Response Are Driven by Baseline [¹⁸F]NaF Parameters: a Pilot Study in Castration-Resistant Prostate Cancer Patients.

Letellier A, Johnson AC, Kit NH, Savigny JF, Batalla A, Parienti JJ, Aide N. Letellier A, et al. Among authors: johnson ac. Mol Imaging Biol. 2018 Jun;20(3):482-491. doi: 10.1007/s11307-017-1132-4. Mol Imaging Biol. 2018. PMID: 29027074

5

Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib.

Emile G, Penager S, Levy C, Johnson A, Allouache D, Lequesne J, Hrab I, Segura C, Morel A, Gunzer K, Faveyrial A, Cherifi F, Da Silva A. Emile G, et al. Oncol Lett. 2022 Jan;23(1):25. doi: 10.3892/ol.2021.13143. Epub 2021 Nov 19. Oncol Lett. 2022. PMID: 34868362 Free PMC article.

6

Predictive factors of ¹⁸F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?

Johnson AC, Dugué AE, Silva M, Moise L, Tillou X, Joly F, Aide N. Johnson AC, et al. EJNMMI Res. 2016 Dec;6(1):84. doi: 10.1186/s13550-016-0237-0. Epub 2016 Nov 21. EJNMMI Res. 2016. PMID: 27873241 Free PMC article.

7

Correction to: Impact of Early Supportive Care Assessment on treatment decision.

Cherifi F, Villemin M, Bisiaux F, Johnson A, Solem Laviec H, Rambeau A. Cherifi F, et al. Support Care Cancer. 2022 Aug;30(8):6555. doi: 10.1007/s00520-022-07119-x. Support Care Cancer. 2022. PMID: 35522345 No abstract available.

8

HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.

Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Boscher C, Dubot-Poitelon C, Rottier P, Lequesne J, Emile G. Cherifi F, et al. BMC Cancer. 2022 Oct 20;22(1):1081. doi: 10.1186/s12885-022-10163-9. BMC Cancer. 2022. PMID: 36266623 Free PMC article.

9

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.

Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.

10

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.

Rottier P, Emile G, Johnson A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Dubot-Poitelon C, Boismoreau L, Cherifi F, Lequesne J, Da Silva A. Rottier P, et al. Front Oncol. 2023 Jan 19;12:1105587. doi: 10.3389/fonc.2022.1105587. eCollection 2022. Front Oncol. 2023. PMID: 36741710 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

617 results

Search Page

Filters